

**From:** John Carson (MBA)  
**To:** Penelope Pearson (PhD)  
**Subject:** BcV-mCov Stage III - Results Report

Good morning Penelope.

I read your technical memo on the Stage III tests for the BcV-mCov vaccine. I must say that, as you know for our previous conversations, I disagree with your interpretation of the results. Population A is representative of the target audience for this vaccine and in that population the results are good enough. There's no need for further testing. The vaccine is safe!

I have decided to authorize the production stage. Make sure everything is ready on your end.

-- John Carson, CEO XFarma

